-
Something wrong with this record ?
Circulating miRNAs as new blood-based biomarkers for solid cancers
M. Redova, J. Sana, O. Slaby,
Language English Country England, Great Britain
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
Grant support
NT13549
MZ0
CEP Register
NT13860
MZ0
CEP Register
Digital library NLK
Full text - Article
Source
NLK
ProQuest Central
from 2005-02-01 to 2020-12-31
Health & Medicine (ProQuest)
from 2005-02-01 to 2020-12-31
PubMed
23469974
DOI
10.2217/fon.12.192
Knihovny.cz E-resources
- MeSH
- Colorectal Neoplasms blood MeSH
- Humans MeSH
- MicroRNAs blood MeSH
- Biomarkers, Tumor blood MeSH
- Lung Neoplasms blood MeSH
- Prostatic Neoplasms blood MeSH
- Breast Neoplasms blood MeSH
- RNA Stability MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Female MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.
References provided by Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc13031555
- 003
- CZ-PrNML
- 005
- 20191029135500.0
- 007
- ta
- 008
- 131002s2013 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.2217/fon.12.192 $2 doi
- 035 __
- $a (PubMed)23469974
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Lojová, Martina, $u Central European Institute of Technology, Masaryk University, Kamenice 5, 625 00, Brno, Czech Republic. $d 1983- $7 mub2011663118
- 245 10
- $a Circulating miRNAs as new blood-based biomarkers for solid cancers / $c M. Redova, J. Sana, O. Slaby,
- 520 9_
- $a miRNAs are short noncoding RNAs that post-transcriptionally regulate gene expression. miRNAs' ability to inhibit translation of oncogenes and tumor suppressor genes implies they have an involvement in carcinogenesis. Specific miRNA expression signatures have been identified in a variety of human cancers. More recently, occurrence of miRNAs in the blood serum and plasma of humans has been repeatedly observed. miRNA levels in serum and plasma are more stable, reproducible and consistent among individuals of the same species in comparison with other circulating nucleic acids. Circulating miRNAs have been successfully evaluated in a wide range of solid cancers as promising novel noninvasive biomarkers of early disease onset or relapse. Here we describe the origin of circulating miRNAs, principles of their immense stability and proposed functions, and comprehensively summarize studies focusing on their significance in the most frequently studied cancer types in this regard, including breast, colorectal, lung and prostate cancer.
- 650 _2
- $a nádory prsu $x krev $7 D001943
- 650 _2
- $a kolorektální nádory $x krev $7 D015179
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a nádory plic $x krev $7 D008175
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a mikro RNA $x krev $7 D035683
- 650 _2
- $a nádory prostaty $x krev $7 D011471
- 650 _2
- $a stabilita RNA $7 D020871
- 650 _2
- $a nádorové biomarkery $x krev $7 D014408
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Šána, Jiří $u - $7 xx0165776
- 700 1_
- $a Slabý, Ondřej, $u - $d 1981- $7 js20030220015
- 773 0_
- $w MED00008687 $t Future oncology (London, England) $x 1744-8301 $g Roč. 9, č. 3 (2013), s. 387-402
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/23469974 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20131002 $b ABA008
- 991 __
- $a 20191029135939 $b ABA008
- 999 __
- $a ok $b bmc $g 995642 $s 830000
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2013 $b 9 $c 3 $d 387-402 $i 1744-8301 $m Future oncology $n Future Oncol $x MED00008687
- GRA __
- $a NT13549 $p MZ0
- GRA __
- $a NT13860 $p MZ0
- LZP __
- $a Pubmed-20131002